{
    "clinical_study": {
        "@rank": "63902", 
        "acronym": "MISER", 
        "arm_group": [
            {
                "arm_group_label": "Endoscopic treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Treated by single transmural cystastrostomy, 12mm balloon dilation (10mm if cystuodenostomy), two 7Fr double pigtail plastic stents and nasocystic drainage catheter."
            }, 
            {
                "arm_group_label": "Minimally invasive surgical necrosectomy", 
                "arm_group_type": "Active Comparator", 
                "description": "First line approach is video assisted retroperitoneal debridement (VARD), or transperitoneal tract debridement.  If this is not possible due to the location of the collection, second line approach is a laproscopic approach.  This includes transperitoneal laproscopy, cystgastrostomy, or transgastric cystgastrostomy with internal debridement."
            }
        ], 
        "brief_summary": {
            "textblock": "Prospective, multi-center randomized controlled trial comparing EUS-Guided cystgastrostomy\n      or cystduodenostomy and endoscopic necrosectomy to minimally invasive surgical necrosectomy,\n      in patients with symptomatic or infected WOPN."
        }, 
        "brief_title": "Minimally Invasive Surgery vs. Endoscopy Randomized (MISER) Trial for Symptomatic Walled-Off Pancreatic Necrosis", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Walled Off Pancreatic Necrosis", 
        "condition_browse": {
            "mesh_term": "Necrosis"
        }, 
        "detailed_description": {
            "textblock": "Patients will be randomly allocated to either treatment arm in a 1:1 ratio.  Following\n      intervention, patients will be assessed at regular intervals intil study completion at 6\n      months post-discharge. Primary outcome is a composite of major complications or mortality,\n      measured to 3 months post-discharge."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Walled off pancreatic necrosis\n\n               -  Symptomatic: Pain, gastric outlet, intestinal or biliary obstruction, new-onset\n                  or persisting organ failure, or 'persisting unwellness'.\n\n               -  Infected (suspected and confirmed): clinical signs of infection (septic,\n                  positive blood cultures, febrile), systemic inflammatory response syndrome, gas\n                  within the collection on imaging (not iatrogenic), or positive culture of\n                  collection contents\n\n          -  Necrotic collection has developed a wall, typically around 4 weeks post presentation,\n             and is within 15mm of the lumen of the gastrointestinal tract.\n\n          -  Informed consent obtained from the patient or their medical representative.\n\n             -> 18 years old\n\n          -  Medically fit for general anesthetic\n\n          -  Collection amenable to either endoscopic or minimally invasive surgical necrosectomy\n             and drainage.\n\n        Exclusion Criteria:\n\n          -  <18 years old\n\n          -  Unable to obtain informed consent from the patient or their medical representative.\n\n          -  Medically unfit for general anesthesia\n\n          -  Pregnant\n\n          -  WOPN collection not accessible by either or both necrosectomy techniques.\n\n          -  The collection has not matured and developed a wall, or is >15mm from the lumen of\n             the gastrointestinal tract.\n\n          -  Irreversible coagulopathy: INR >1.5\n\n          -  Irreversible thrombocytopenia: platelet count <50 x109/L, thrombocytopenia confirmed\n             by manual count.\n\n          -  Dual antiplatelet therapy or therapeutic anticoagulation that cannot be withheld for\n             the procedure\n\n          -  Surgical or endoscopic necrosectomy or pseudocyst drainage has been performed within\n             the preceding 12 months\n\n          -  WOPN secondary to trauma or other surgical event that requires additional\n             interventions such as management of liver lacerations or vascular injury."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084537", 
            "org_study_id": "577235"
        }, 
        "intervention": [
            {
                "arm_group_label": "Endoscopic treatment", 
                "description": "Treated by single transmural cystgastrostomy, 12mm balloon dilation (10mm if cystduodenostomy), two 7fr double pigtail plastic stents and nasocystic drainage catheter.", 
                "intervention_name": "Endoscopic treatment", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "Endoscopic cystgastrostomy", 
                    "Endoscopic cystduodenostomy"
                ]
            }, 
            {
                "arm_group_label": "Minimally invasive surgical necrosectomy", 
                "description": "First line approach is video assisted retroperitoneal debridement (VARD), or transperitoneal tract debridement.\nIf this is not possible due to the location of the collection, second line approach is a laparoscopic approach. This includes transperitoneal laparoscopy cystgastrostomy, or transgastric cystgastrostomy with internal debridement.  If percutaneous tract access and debridement is planned, surgery is to be performed no later than 48 hours after interventional radiology insert percutaneous drain.", 
                "intervention_name": "Minimally invasive surgical necrosectomy", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "video assisted retroperitoneal debridement (VARD)", 
                    "transperitoneal tract debridement", 
                    "laparoscopic approach", 
                    "transperitoneal laparoscopy cystgastrostomy", 
                    "transgastric cystgastrostomy with internal debridement"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "symptomatic", 
            "infected", 
            "necrotic collection"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": {
            "contact": {
                "email": "amy.logue@flhosp.org", 
                "last_name": "Amy L Logue, RN, MSN", 
                "phone": "407-303-9736"
            }, 
            "contact_backup": {
                "email": "shyam.vaaradarajulu.MD@flhosp.org", 
                "last_name": "Shyam S Varadarajulu, MD", 
                "phone": "407-303-2570"
            }, 
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "34786"
                }, 
                "name": "Florida Hospital Center for Interventional Endoscopy"
            }, 
            "investigator": {
                "last_name": "Shyam S Varadarajulu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Minimally Invasive Surgeryvs. Endoscopy Randomized (MISER) Trial for Symptomatic Walled-Off Pancreatic Necrosis", 
        "overall_contact": {
            "email": "shyam.varadarajulu.md@flhosp.org", 
            "last_name": "Shyam S Varadarajulu, MD", 
            "phone": "407-303-2570"
        }, 
        "overall_contact_backup": {
            "email": "amy.logue@flhosp.org", 
            "last_name": "Amy L Logue, RN, MSN", 
            "phone": "407-303-9736"
        }, 
        "overall_official": {
            "affiliation": "Florida Hospital", 
            "last_name": "Shyam S Varadarajulu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite of major complications and mortality (all cause and disease specific), measured to 3 months post discharge", 
            "measure": "Major complications", 
            "safety_issue": "Yes", 
            "time_frame": "3 months post discharge"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084537"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Florida Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Alabama at Birmingham", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Johns Hopkins University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Florida Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}